Kalypsys, Inc. has announced that it has entered into a collaboration agreement with the objective of delivering ophthalmic drug candidates for development and commercialization by Alcon Research, Ltd. and Alcon Manufacturing, Ltd., which are affiliates of Alcon, Inc.
Under terms of a four year agreement, Kalypsys will receive an access fee, research support, and milestone payments.
In addition, Kalypsys will receive royalty payments on net sales of commercial products. An additional component of the agreement gives Alcon preferred partnering access to compounds from Kalypsys programs.
"We are pleased that Alcon has partnered with Kalypsys to gain access to our technology, capabilities, and approach to drug discovery," commented John McKearn, President and CEO of Kalypsys.
"Moreover, Alcon's access to Kalypsys programs amplifies the value of our pipeline and establishes a relationship to partner Kalypsys compounds with the premiere company in ophthalmology."
"We intend to enter into a limited number of important alliances in other therapeutic fields in the next 12-18 months and we are delighted that Alcon represents the first of our expected agreements."
In the collaboration, Kalypsys will use its uHTS technology and chemical library to identify and profile active molecules against collaboration targets.
Kalypsys will also apply its medicinal chemistry and other drug discovery capabilities in partnership with Alcon's research capabilities and expertise in ophthalmology.
Alcon will be responsible for all development, manufacturing, and commercialization of products.
"In our view, Kalypsys offers a unique combination of an experienced management team and world-class pharmaceutical technology to create a powerful drug discovery engine that we envision will help grow and advance our expected pipeline of novel and important drugs to treat diseases of the eye," said Martin B. Wax M.D., Alcon's Vice President of R&D and head of Ophthalmology Discovery Research.